Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Inclusion Criteria: * healthy male subjects as determined by results of screening * signed written informed consent in accordance with GCP and local legislation * age \>= 18 and \<= 50 years * Broca \>= - 20% and \<0 + 20% Exclusion Criteria: * any finding of the medical examination (including blood pressure, pulse rate and ECG) * history or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders * history of orthostatic hypotension, fainting spells and blackouts * diseases of central nervous system (such as epilepsy) or psychiatric disorders * chronic or relevant acute infections * History of: * allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * any bleeding disorder including prolonged or habitual bleeding * other hematologic disease * cerebral bleeding (e.g. after a car accident) * commotio cerebri * intake of drugs with a long half-life (\>24 hours) within 1 month prior to administration * use of any drugs which might influence the results of the trial within 10 days prior to administration or during administration * participation in another trial with an investigational drug within 2 month prior to administration or during trial * smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days * alcohol abuse (\>60 g / day) * drug abuse * blood donation within 1 month prior to administration or during the trial * excessive physical activities within 5 days prior to administration or during the trial * any laboratory value outside the clinically accepted reference range * history of any familial bleeding disorder * Thrombocytes \< 150000 /µl